JP2017503786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503786A5 JP2017503786A5 JP2016541128A JP2016541128A JP2017503786A5 JP 2017503786 A5 JP2017503786 A5 JP 2017503786A5 JP 2016541128 A JP2016541128 A JP 2016541128A JP 2016541128 A JP2016541128 A JP 2016541128A JP 2017503786 A5 JP2017503786 A5 JP 2017503786A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- benzo
- dioxide
- dihydro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-oxotetrahydrofuran-3-yl Chemical group 0.000 claims description 413
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 266
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 158
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 138
- 235000019260 propionic acid Nutrition 0.000 claims description 135
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 123
- 150000001875 compounds Chemical class 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- KBUVKGMVZDAWOJ-UHFFFAOYSA-N 3h-oxathiazepine Chemical compound C=1C=COSNC=1 KBUVKGMVZDAWOJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 57
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000005936 piperidyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 2
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 2
- HXXOPVULXOEHTK-UHFFFAOYSA-N 4-methyl-1,3-dioxol-2-one Chemical compound CC1=COC(=O)O1 HXXOPVULXOEHTK-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 208000032376 Lung infection Diseases 0.000 claims 2
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- YXGFOCDXNTYPPR-UHFFFAOYSA-N (1-methylpyrrolidin-3-yl) propanoate Chemical compound CCC(=O)OC1CCN(C)C1 YXGFOCDXNTYPPR-UHFFFAOYSA-N 0.000 claims 1
- RZDVYTYOVMEPBY-HSZRJFAPSA-N (3R)-3-[3-[[benzenesulfonyl(methyl)amino]methyl]-4-methylphenyl]-3-(1,4-dimethylbenzotriazol-5-yl)propanoic acid Chemical compound CN1N=NC2=C1C=CC(=C2C)[C@H](CC(=O)O)C1=CC(=C(C=C1)C)CN(S(=O)(=O)C1=CC=CC=C1)C RZDVYTYOVMEPBY-HSZRJFAPSA-N 0.000 claims 1
- RZDVYTYOVMEPBY-QHCPKHFHSA-N (3S)-3-[3-[[benzenesulfonyl(methyl)amino]methyl]-4-methylphenyl]-3-(1,4-dimethylbenzotriazol-5-yl)propanoic acid Chemical compound CN1N=NC2=C1C=CC(=C2C)[C@@H](CC(=O)O)C1=CC(=C(C=C1)C)CN(S(=O)(=O)C1=CC=CC=C1)C RZDVYTYOVMEPBY-QHCPKHFHSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ASHQFKBZKJYEQG-UHFFFAOYSA-N 2-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C2N(C)N=NC2=C1 ASHQFKBZKJYEQG-UHFFFAOYSA-N 0.000 claims 1
- UVSPBAFXKQMDBG-UHFFFAOYSA-N 2-(dimethylamino)ethyl propanoate Chemical compound CCC(=O)OCCN(C)C UVSPBAFXKQMDBG-UHFFFAOYSA-N 0.000 claims 1
- SFAMKDPMPDEXGH-UHFFFAOYSA-N 2-hydroxyethyl propanoate Chemical compound CCC(=O)OCCO SFAMKDPMPDEXGH-UHFFFAOYSA-N 0.000 claims 1
- SFUSXTAJJNOGFY-UHFFFAOYSA-N 3-(1,4-dimethylbenzotriazol-5-yl)-3-[3-[[2-hydroxyethyl-(2-methoxypyridin-3-yl)sulfonylamino]methyl]-4-methylphenyl]propanoic acid Chemical compound CN1N=NC2=C1C=CC(=C2C)C(CC(=O)O)C1=CC(=C(C=C1)C)CN(S(=O)(=O)C=1C(=NC=CC=1)OC)CCO SFUSXTAJJNOGFY-UHFFFAOYSA-N 0.000 claims 1
- VYACXBSULJEWPY-UHFFFAOYSA-N 3-(1,4-dimethylbenzotriazol-5-yl)-3-[4-methyl-3-[(5-methyl-3,4-dihydro-1,2,5-benzothiadiazepin-2-yl)methyl]phenyl]propan-1-ol Chemical compound CN1N=NC2=C1C=CC(=C2C)C(CCO)C=1C=CC(=C(CN2SC3=C(N(CC2)C)C=CC=C3)C=1)C VYACXBSULJEWPY-UHFFFAOYSA-N 0.000 claims 1
- XZLRJCSXDLXBSC-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl 2-cyanoacetate Chemical group CC(C)(C)OC(=O)NCCCOC(=O)CC#N XZLRJCSXDLXBSC-UHFFFAOYSA-N 0.000 claims 1
- CCKFFZWASQCQFD-UHFFFAOYSA-N 3-[3-[[(3-acetamidophenyl)sulfonyl-methylamino]methyl]-4-chlorophenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound C(C)(=O)NC=1C=C(C=CC=1)S(=O)(=O)N(C)CC=1C=C(C=CC=1Cl)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1 CCKFFZWASQCQFD-UHFFFAOYSA-N 0.000 claims 1
- AEWQYTMJBRTVCM-UHFFFAOYSA-N 3-[3-[[2-hydroxyethyl-(2-methoxypyridin-3-yl)sulfonylamino]methyl]-4-methylphenyl]-3-(7-methoxy-1-methylbenzotriazol-5-yl)propanoic acid Chemical compound OCCN(S(=O)(=O)C=1C(=NC=CC=1)OC)CC=1C=C(C=CC=1C)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C(=C1)OC AEWQYTMJBRTVCM-UHFFFAOYSA-N 0.000 claims 1
- QJFXAWTUFRGEDO-UHFFFAOYSA-N 3-[3-[[benzenesulfonyl(methyl)amino]methyl]-4-methylphenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound CN1N=NC2=C1C=CC(=C2)C(CC(=O)O)C1=CC(=C(C=C1)C)CN(S(=O)(=O)C1=CC=CC=C1)C QJFXAWTUFRGEDO-UHFFFAOYSA-N 0.000 claims 1
- TYEFYUBZAKPDAX-UHFFFAOYSA-N 3-[3-[[cyclopentylsulfonyl(methyl)amino]methyl]-4-methylphenyl]-3-(1,4-dimethylbenzotriazol-5-yl)propanoic acid Chemical compound CN1N=NC2=C1C=CC(=C2C)C(CC(=O)O)C1=CC(=C(C=C1)C)CN(S(=O)(=O)C1CCCC1)C TYEFYUBZAKPDAX-UHFFFAOYSA-N 0.000 claims 1
- SRPXGGSRYJJWSO-UHFFFAOYSA-N 3-[4-chloro-3-[[(1,5-dimethylpyrazol-4-yl)sulfonyl-methylamino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C=1C=NN(C=1C)C)C SRPXGGSRYJJWSO-UHFFFAOYSA-N 0.000 claims 1
- CPQNNJBTSHDTLZ-UHFFFAOYSA-N 3-[4-chloro-3-[[2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl(methyl)amino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C1=CC2=C(OCCO2)C=C1)C CPQNNJBTSHDTLZ-UHFFFAOYSA-N 0.000 claims 1
- MLPSEERETBAFEP-UHFFFAOYSA-N 3-[4-chloro-3-[[2,3-dihydro-1H-inden-5-ylsulfonyl(methyl)amino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C=1C=C2CCCC2=CC=1)C MLPSEERETBAFEP-UHFFFAOYSA-N 0.000 claims 1
- XDOGAMNAMXXKOO-UHFFFAOYSA-N 3-[4-chloro-3-[[ethyl(pyridin-3-ylsulfonyl)amino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C=1C=NC=CC=1)CC XDOGAMNAMXXKOO-UHFFFAOYSA-N 0.000 claims 1
- USDLDJOPUXHGLC-UHFFFAOYSA-N 3-[4-chloro-3-[[methyl(methylsulfonyl)amino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C)C USDLDJOPUXHGLC-UHFFFAOYSA-N 0.000 claims 1
- LALJNFCDDXCGMH-UHFFFAOYSA-N 3-[4-chloro-3-[[methyl-(3-methylphenyl)sulfonylamino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C1=CC(=CC=C1)C)C LALJNFCDDXCGMH-UHFFFAOYSA-N 0.000 claims 1
- FKGLABWENBSNRH-UHFFFAOYSA-N 3-[4-chloro-3-[[methyl-(4-methylphenyl)sulfonylamino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C1=CC=C(C=C1)C)C FKGLABWENBSNRH-UHFFFAOYSA-N 0.000 claims 1
- FRBDZDVSXHHBHW-UHFFFAOYSA-N 3-[4-chloro-3-[[propyl(pyridin-3-ylsulfonyl)amino]methyl]phenyl]-3-(1-methylbenzotriazol-5-yl)propanoic acid Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)O)C1=CC2=C(N(N=N2)C)C=C1)CN(S(=O)(=O)C=1C=NC=CC=1)CCC FRBDZDVSXHHBHW-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- HBOBNYBQNVWMAG-UHFFFAOYSA-N CCC(C1=CC(=C(C=C1)C)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C(=C3)OC)N(N=N4)C Chemical compound CCC(C1=CC(=C(C=C1)C)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C(=C3)OC)N(N=N4)C HBOBNYBQNVWMAG-UHFFFAOYSA-N 0.000 claims 1
- SEKQCRHQWAMDJD-UHFFFAOYSA-N CCC(C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2CCCCC2)C3=CC4=C(C=C3)N(N=N4)C Chemical compound CCC(C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2CCCCC2)C3=CC4=C(C=C3)N(N=N4)C SEKQCRHQWAMDJD-UHFFFAOYSA-N 0.000 claims 1
- QELVGHPHZFVKIU-NRFANRHFSA-N CC[C@@H](C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C=C3)N(N=N4)C Chemical compound CC[C@@H](C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C=C3)N(N=N4)C QELVGHPHZFVKIU-NRFANRHFSA-N 0.000 claims 1
- QELVGHPHZFVKIU-OAQYLSRUSA-N CC[C@H](C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C=C3)N(N=N4)C Chemical compound CC[C@H](C1=CC(=C(C=C1)Cl)CN(C)S(=O)(=O)C2=CC=CC=C2)C3=CC4=C(C=C3)N(N=N4)C QELVGHPHZFVKIU-OAQYLSRUSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010072082 Environmental exposure Diseases 0.000 claims 1
- 206010073306 Exposure to radiation Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- DZABSSLCAIHBIK-UHFFFAOYSA-N pyrrolidin-3-ylmethyl propanoate Chemical compound CCC(=O)OCC1CCNC1 DZABSSLCAIHBIK-UHFFFAOYSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000014759 maintenance of location Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 239000012267 brine Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000534944 Thia Species 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ANOZGSVWIWKADP-UHFFFAOYSA-N 3-(3-methylphenyl)propan-1-ol Chemical compound CC1=CC=CC(CCCO)=C1 ANOZGSVWIWKADP-UHFFFAOYSA-N 0.000 description 2
- SXJVPOQSRCPRNC-UHFFFAOYSA-N CC(C(C=CC(O)=O)=C1)=NC=C1OC Chemical compound CC(C(C=CC(O)=O)=C1)=NC=C1OC SXJVPOQSRCPRNC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000011986 second-generation catalyst Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- KODLUXHSIZOKTG-SCSAIBSYSA-N (2r)-1-aminobutan-2-ol Chemical compound CC[C@@H](O)CN KODLUXHSIZOKTG-SCSAIBSYSA-N 0.000 description 1
- SCHBQPIVMBDOQF-UHFFFAOYSA-N (5-bromo-2-chlorophenyl)methanol Chemical compound OCC1=CC(Br)=CC=C1Cl SCHBQPIVMBDOQF-UHFFFAOYSA-N 0.000 description 1
- JSXAJLMUBSEJFF-UHFFFAOYSA-N 1-fluoro-3-methyl-2-nitrobenzene Chemical compound CC1=CC=CC(F)=C1[N+]([O-])=O JSXAJLMUBSEJFF-UHFFFAOYSA-N 0.000 description 1
- RLWFAPGDEACWRU-UHFFFAOYSA-N 2-chloro-N-(2-hydroxybutyl)pyridine-3-sulfonamide Chemical compound ClC1=NC=CC=C1S(=O)(=O)NCC(CC)O RLWFAPGDEACWRU-UHFFFAOYSA-N 0.000 description 1
- MFJSIQDQIZEVJX-UHFFFAOYSA-N 2-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=CC=C1S(Cl)(=O)=O MFJSIQDQIZEVJX-UHFFFAOYSA-N 0.000 description 1
- CMVJYZNBMRJICR-UHFFFAOYSA-N 2-fluoro-6-methylaniline Chemical compound CC1=CC=CC(F)=C1N CMVJYZNBMRJICR-UHFFFAOYSA-N 0.000 description 1
- VWXVTHDQAOAENP-UHFFFAOYSA-N 3-(3-methylphenyl)propanoic acid Chemical compound CC1=CC=CC(CCC(O)=O)=C1 VWXVTHDQAOAENP-UHFFFAOYSA-N 0.000 description 1
- FTRGCQAVQAKQBH-UHFFFAOYSA-N 3-bromo-5-methoxy-2-methylpyridine Chemical compound COC1=CN=C(C)C(Br)=C1 FTRGCQAVQAKQBH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HTVJDAQMMNMEBZ-UHFFFAOYSA-N 3-methyl-2-nitrobenzamide Chemical compound CC1=CC=CC(C(N)=O)=C1[N+]([O-])=O HTVJDAQMMNMEBZ-UHFFFAOYSA-N 0.000 description 1
- DGDAVTPQCQXLGU-UHFFFAOYSA-N 5437-38-7 Chemical compound CC1=CC=CC(C(O)=O)=C1[N+]([O-])=O DGDAVTPQCQXLGU-UHFFFAOYSA-N 0.000 description 1
- YWEHDKANKNNTMY-UHFFFAOYSA-N 7-methoxy-1,4-dimethylbenzotriazole Chemical compound COC1=CC=C(C2=C1N(N=N2)C)C YWEHDKANKNNTMY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)=*C(*CCN1C)=C(*=*)S1(=O)=O Chemical compound CC(C)=*C(*CCN1C)=C(*=*)S1(=O)=O 0.000 description 1
- AOIYGWQJFVVUFU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)B1CC(C(C1)(C)C)(C)C)CO Chemical compound ClC1=C(C=C(C=C1)B1CC(C(C1)(C)C)(C)C)CO AOIYGWQJFVVUFU-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AKLVZYMHMBFHCT-GQCTYLIASA-N methyl (E)-3-(1-methylbenzotriazol-5-yl)prop-2-enoate Chemical compound CN1N=NC2=C1C=CC(=C2)/C=C/C(=O)OC AKLVZYMHMBFHCT-GQCTYLIASA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- DCTZQTMHRDQEFC-UHFFFAOYSA-N methyl 3-(4-cyano-2-methylphenyl)-3-[3-(hydroxymethyl)-4-methylphenyl]propanoate Chemical compound C(#N)C1=CC(=C(C=C1)C(CC(=O)OC)C1=CC(=C(C=C1)C)CO)C DCTZQTMHRDQEFC-UHFFFAOYSA-N 0.000 description 1
- LKRRWOQDXNKFRD-UHFFFAOYSA-N methyl 3-[4-chloro-3-(hydroxymethyl)phenyl]-3-(1-methylbenzotriazol-5-yl)propanoate Chemical compound ClC1=C(C=C(C=C1)C(CC(=O)OC)C1=CC2=C(N(N=N2)C)C=C1)CO LKRRWOQDXNKFRD-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- ITMONGJWFZBCRS-UHFFFAOYSA-N n-[2-nitro-3-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C(F)(F)F)=C1[N+]([O-])=O ITMONGJWFZBCRS-UHFFFAOYSA-N 0.000 description 1
- QWQOZAZPFJLGRB-UHFFFAOYSA-N n-methyl-n-[2-nitro-3-(trifluoromethyl)phenyl]acetamide Chemical compound CC(=O)N(C)C1=CC=CC(C(F)(F)F)=C1[N+]([O-])=O QWQOZAZPFJLGRB-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 description 1
- CDRNYKLYADJTMN-UHFFFAOYSA-N pyridine-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CN=C1 CDRNYKLYADJTMN-UHFFFAOYSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917466P | 2013-12-18 | 2013-12-18 | |
| US61/917,466 | 2013-12-18 | ||
| US201461980091P | 2014-04-16 | 2014-04-16 | |
| US61/980,091 | 2014-04-16 | ||
| PCT/IB2014/067027 WO2015092713A1 (en) | 2013-12-18 | 2014-12-17 | Nrf2 regulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503786A JP2017503786A (ja) | 2017-02-02 |
| JP2017503786A5 true JP2017503786A5 (enExample) | 2018-02-15 |
| JP6630671B2 JP6630671B2 (ja) | 2020-01-15 |
Family
ID=52355021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541128A Active JP6630671B2 (ja) | 2013-12-18 | 2014-12-17 | Ｎｒｆ２レギュレーター |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10144731B2 (enExample) |
| EP (1) | EP3083614B1 (enExample) |
| JP (1) | JP6630671B2 (enExample) |
| KR (1) | KR102301867B1 (enExample) |
| CN (1) | CN105829305B (enExample) |
| AU (2) | AU2014369153B2 (enExample) |
| BR (1) | BR112016014180A2 (enExample) |
| CA (1) | CA2934216C (enExample) |
| CL (1) | CL2016001516A1 (enExample) |
| CR (1) | CR20160272A (enExample) |
| DO (1) | DOP2016000145A (enExample) |
| EA (1) | EA030431B1 (enExample) |
| ES (1) | ES2784244T3 (enExample) |
| IL (1) | IL245727B (enExample) |
| MX (1) | MX370410B (enExample) |
| PE (1) | PE20160901A1 (enExample) |
| PH (1) | PH12016501151A1 (enExample) |
| SG (1) | SG11201604611SA (enExample) |
| WO (1) | WO2015092713A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137557B (zh) | 2015-06-15 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| CA2988338C (en) | 2015-06-15 | 2024-05-14 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| JP2018517732A (ja) * | 2015-06-15 | 2018-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーター |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2017060855A1 (en) * | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| CN105566241B (zh) * | 2016-01-18 | 2018-05-25 | 中国药科大学 | 1-磺酰胺基-4-芳氧基类化合物、制备方法及其医药用途 |
| HUE052269T2 (hu) | 2016-02-03 | 2021-04-28 | Rigel Pharmaceuticals Inc | NRF2-t aktiváló vegyületek és alkalmazásuk |
| WO2018104766A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
| WO2018109641A1 (en) * | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| WO2018109642A1 (en) * | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| US11117905B2 (en) * | 2016-12-14 | 2021-09-14 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as NRF2 activators |
| JP2020502129A (ja) * | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２アクチベーターとしての３−オキソ−１，４−ジアゼピニル化合物 |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| AU2017376900A1 (en) * | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| WO2018145109A1 (en) | 2017-02-06 | 2018-08-09 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| US20210177861A1 (en) * | 2017-12-11 | 2021-06-17 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| US11643407B2 (en) | 2018-05-23 | 2023-05-09 | Glaxosmithkline Intellectual Property Development Limited | Indanes as NRF2 activators |
| AU2019307631A1 (en) | 2018-07-20 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via KEAP1 |
| MX2021002060A (es) * | 2018-08-20 | 2021-07-21 | Janssen Pharmaceutica Nv | Inhibidores de la interacción proteína-proteína keap1-nrf2. |
| CA3121952C (en) * | 2018-12-05 | 2025-05-13 | Scohia Pharma, Inc. | MACROCYCLICAL COMPOUND AND ITS USES |
| CN113474349B (zh) | 2019-02-15 | 2024-03-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 |
| EP3953337A4 (en) * | 2019-04-08 | 2023-08-09 | Dana-Farber Cancer Institute, Inc. | Degraders of kelch-like ech-associated protein 1 (keap1) |
| BR112021023927A2 (pt) | 2019-05-31 | 2022-02-08 | Ube Industries | Composto, e, composição farmacêutica |
| EP3998262A4 (en) * | 2019-07-03 | 2023-07-26 | Senju Pharmaceutical Co., Ltd. | NRF2 ACTIVATING COMPOUND |
| EP4110776A1 (en) * | 2020-02-28 | 2023-01-04 | Les Laboratoires Servier | New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them |
| CR20230158A (es) * | 2020-09-14 | 2023-07-13 | Sanofi Sa | Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias |
| JP7681044B2 (ja) * | 2020-12-28 | 2025-05-21 | 千寿製薬株式会社 | Ｎｒｆ２活性化化合物 |
| WO2023210741A1 (ja) | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| US20250296939A1 (en) | 2022-04-28 | 2025-09-25 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| CN117603075B (zh) * | 2024-01-18 | 2024-04-12 | 深圳创元生物医药科技有限公司 | 一种碳13标记的3-羧酸苯丙氨酸的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| WO1993012075A1 (fr) | 1991-12-10 | 1993-06-24 | Shionogi & Co., Ltd. | Derive d'acide hydroxamique a base de sulfonamide aromatique |
| JPH10501222A (ja) | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| EP1360173A2 (en) | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| JPWO2002080899A1 (ja) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| CN110894196A (zh) | 2001-09-21 | 2020-03-20 | 百时美-施贵宝控股爱尔兰无限公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| TWI320039B (en) | 2001-09-21 | 2010-02-01 | Lactam-containing compounds and derivatives thereof as factor xa inhibitors | |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| WO2004007464A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | イミダゾール誘導体 |
| WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
| WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| WO2009089192A1 (en) | 2008-01-07 | 2009-07-16 | Ligand Pharmaceuticals Inc. | 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders |
| WO2010005922A1 (en) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| EP2321267A2 (en) * | 2008-08-15 | 2011-05-18 | F. Hoffmann-La Roche AG | Monoaryl aminotetralines |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| KR101837759B1 (ko) * | 2010-02-18 | 2018-04-26 | 브이티브이 테라퓨틱스 엘엘씨 | 치환된 융합 이미다졸 유도체, 약학적 조성물, 및 그것의 사용 방법 |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013067036A1 (en) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| EP2816023A4 (en) * | 2012-02-13 | 2015-09-09 | Takeda Pharmaceutical | AROMATIC RING CONNECTION |
| WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
-
2014
- 2014-12-17 AU AU2014369153A patent/AU2014369153B2/en active Active
- 2014-12-17 US US15/105,306 patent/US10144731B2/en active Active
- 2014-12-17 CN CN201480069879.3A patent/CN105829305B/zh active Active
- 2014-12-17 SG SG11201604611SA patent/SG11201604611SA/en unknown
- 2014-12-17 KR KR1020167018852A patent/KR102301867B1/ko active Active
- 2014-12-17 WO PCT/IB2014/067027 patent/WO2015092713A1/en not_active Ceased
- 2014-12-17 PE PE2016000789A patent/PE20160901A1/es unknown
- 2014-12-17 JP JP2016541128A patent/JP6630671B2/ja active Active
- 2014-12-17 BR BR112016014180A patent/BR112016014180A2/pt active Search and Examination
- 2014-12-17 EA EA201691259A patent/EA030431B1/ru not_active IP Right Cessation
- 2014-12-17 MX MX2016008134A patent/MX370410B/es active IP Right Grant
- 2014-12-17 EP EP14827868.2A patent/EP3083614B1/en active Active
- 2014-12-17 CR CR20160272A patent/CR20160272A/es unknown
- 2014-12-17 ES ES14827868T patent/ES2784244T3/es active Active
- 2014-12-17 CA CA2934216A patent/CA2934216C/en active Active
-
2016
- 2016-05-19 IL IL24572716A patent/IL245727B/en active IP Right Grant
- 2016-06-14 PH PH12016501151A patent/PH12016501151A1/en unknown
- 2016-06-15 CL CL2016001516A patent/CL2016001516A1/es unknown
- 2016-06-17 DO DO2016000145A patent/DOP2016000145A/es unknown
-
2017
- 2017-12-20 AU AU2017279668A patent/AU2017279668B2/en active Active
-
2018
- 2018-09-06 US US16/122,968 patent/US20190002454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503786A5 (enExample) | ||
| JP7369743B2 (ja) | 置換４－アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| AU2017279668B2 (en) | Nrf2 regulators | |
| US9663523B2 (en) | BET protein-inhibiting 5-aryltriazoleazepines | |
| KR101156230B1 (ko) | 융합된 헤테로사이클 화합물 | |
| AU2018351400A1 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| EA036445B1 (ru) | ПРОИЗВОДНЫЕ 4-АМИНО-2-(1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ)-6-ОКСО-6,7-ДИГИДРО-5H-ПИРРОЛО[2,3-d]ПИРИМИДИНА И СООТВЕТСТВУЮЩИЕ ПРОИЗВОДНЫЕ (1H-ИНДАЗОЛ-3-ИЛА) В КАЧЕСТВЕ МОДУЛЯТОРОВ cGMP ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ | |
| EP2491034A1 (en) | Fused heterocyclic compounds as orexin receptor modulators | |
| JP2021514346A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼｍｋｋ４阻害剤 | |
| AU2015267305A1 (en) | Factor XIa inhibitors | |
| EP3083573B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
| ES2976515T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ | |
| CN109384803A (zh) | Atx抑制剂及其制备方法和应用 | |
| KR20240124952A (ko) | Hdac6 억제제로서의 화합물 및 이의 용도 | |
| AU2017376446A1 (en) | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | |
| WO2018226771A1 (en) | Pyrazolopyrimidine pde9 inhibitors | |
| TW202019928A (zh) | αvβ6整合素之抑制劑 | |
| HK40061670B (zh) | 用於治疗与apj受体活性有关的疾病的化合物和组合物 |